⚠️ FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN USE.

How to Evaluate Peptide COAs

COA Evaluation Guide

How to evaluate peptide COAs and batch documentation.

This is the education page: a vendor-neutral framework for reviewing research-use material documentation, independent verification, test methods, report limits, and red flags. It is not protocol, dosing, treatment, administration, or human-use guidance.

Start with the batch-specific COA.

A credible supplier should make batch-level documentation easy to review before purchase. The report should identify the material tested, the analytical method used, and the measured result.

Batch match

The COA should match the product name and batch or lot being sold.

Independent lab

The report should come from a third-party analytical laboratory, not unsupported in-house claims.

Methods shown

Look for stated methods such as HPLC purity, identity confirmation, content analysis, endotoxin, or heavy-metal screening.

Verification path

A direct lab-hosted link is stronger than a copied screenshot or “available on request.”

What a COA can and cannot confirm.

Good documentation is not just a high number. It is knowing what the report establishes and what it does not.

COA elementCan supportDo not assume
Product and batchConnection to a named material or release.Every vial or later handling condition.
HPLC purityMeasured purity profile of the submitted sample.Sterility, endotoxin, heavy metals, or stability.
Identity / compositionAnalytical confirmation where included.Therapeutic effect, safety, or human-use suitability.
Content / concentrationMeasured amount or concentration.Purity or contaminant coverage unless separately measured.
Endotoxin / heavy metalsSpecific screening result when tested.Broad safety claims or sterility.

Transparent research-use documentation checklist.

Clear naming

Product names, labels, COAs, and product pages should line up.

Amount disclosure

Form and amount should be visible, especially where content is tested.

Published reports

Public batch reports are stronger than vague claims or private-only documentation.

Research-use boundaries

Commerce pages should avoid dosing, administration, treatment, outcome, or human-use framing.

Common red flags.

No batch-specific COA

Generic sample reports do not create a clean proof trail.

No verification path

Untraceable reports are easier to manipulate or misrepresent.

Overbroad claims

“Tested” should not imply sterility or contaminant screening unless shown.

Non-research framing

Application instructions or therapeutic outcomes on commerce pages are a warning sign.

How Chameleon organizes documentation.

We separate the lab evidence, our process, and this evaluation guide so each page has one job.

  • COA Library: batch reports, results, Janoshik verification, and product links.
  • Quality Standard: supplier screening, release process, custody, and limits.
  • COA Evaluation Guide: vendor-neutral checklist and red flags.

Choose your next step.

Need the actual Chameleon report? Open the COA Library. Want to understand our release process? Read the Quality Standard.